Sano Healthcare announced that in the first three quarters of 2026, it achieved operating income of 450 million yuan, an increase of 23.66%; net profit attributable to shareholders of listed companies was 69.1452 million yuan, an increase of 227.42% year on year; and net profit after deducting non-recurring profit and loss increased 371.51% year on year. Quarterly revenue for the third quarter of 2026 was 145 million yuan, up 63.27% year on year; net profit to mother increased 158.63% year over year. R&D investment in the first three quarters was 89.592 million yuan, a year-on-year decrease of 30.76%. R&D investment accounted for 19.91% of revenue, a year-on-year decrease of 15.66 percentage points.

Sano Healthcare announced that in the first three quarters of 2026, it achieved operating income of 450 million yuan, an increase of 23.66%; net profit attributable to shareholders of listed companies was 69.1452 million yuan, an increase of 227.42% year on year; and net profit after deducting non-recurring profit and loss increased 371.51% year on year. Quarterly revenue for the third quarter of 2026 was 145 million yuan, up 63.27% year on year; net profit to mother increased 158.63% year over year. R&D investment in the first three quarters was 89.592 million yuan, a year-on-year decrease of 30.76%. R&D investment accounted for 19.91% of revenue, a year-on-year decrease of 15.66 percentage points.